ReviewCureus2026
The Atopic Dermatitis Patient Journey: From Awareness to Advanced Care.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient Experience and Preferences for Treatments in Atopic Dermatitis.Dermatology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impacts the physical, psychological, and social well-being of patients. While clinical guidelines offer structured treatment pathways, real-world patient experiences often differ from clinical expectations due to delayed diagnosis, misinformation, inconsistent care, and emotional distress. This narrative review explores the full spectrum of the AD patient journey, from pre-diagnosis awareness to maintenance therapy and advanced treatment access, highlighting the barriers patients face in navigating care. These include medical, psychological, financial, and systemic obstacles that impair treatment adherence and reduce quality of life (QoL). The importance of early recognition by primary care providers, timely referrals to dermatologists, and patient-centered communication is emphasized. Advancements in topical, systemic, and biologic therapies have transformed the therapeutic landscape; however, fears around steroid use, cost-related limitations, and inadequate care coordination persist. A shift toward proactive management, integration of teledermatology, and patient education programs can bridge the gap between clinical recommendations and real-world outcomes. Understanding the patient journey is essential for developing more inclusive and effective care models that improve long-term disease control and patient QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.